The Current Ratio as of September 2024 (TTM) for Xeris Biopharma Holdings, Inc. (XERS) is 2.26

According to Xeris Biopharma Holdings, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.26. This represents a change of 11.64% compared to the average of 2.02 of the last 4 quarters.

Xeris Biopharma Holdings, Inc. (XERS) Historical Current Ratio (quarterly & annually)

How has XERS Current Ratio performed in the past?

The mean historical Current Ratio of Xeris Biopharma Holdings, Inc. over the last ten years is 5.96. The current 2.26 Current Ratio has changed 3.68% with respect to the historical average. Over the past ten years (40 quarters), XERS's Current Ratio was at its highest in in the September 2018 quarter at 16.53. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Xeris Biopharma Holdings, Inc. (XERS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Xeris Biopharma Holdings, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xeris Biopharma Holdings, Inc. (XERS) Average Current Ratio

How has XERS Current Ratio performed in the past?

The current Current Ratio of Xeris Biopharma Holdings, Inc. (XERS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xeris Biopharma Holdings, Inc. (XERS) Current Ratio vs. Peers

How is XERS’s Current Ratio compared to its peers?

Xeris Biopharma Holdings, Inc.’s Current Ratio is greater than Protalix BioTherapeutics, Inc. (1.33), greater than Seres Therapeutics, Inc. (1.38), less than Cidara Therapeutics, Inc. (4.25), less than ImmunityBio, Inc. (3.91), less than Galera Therapeutics, Inc. (5.63), less than Mereo BioPharma Group plc (6.07), less than Terns Pharmaceuticals, Inc. (21.02), less than PDS Biotechnology Corporation (3.84), less than Inozyme Pharma, Inc. (9.84), less than HOOKIPA Pharma Inc. (3.86), less than X4 Pharmaceuticals, Inc. (6.07), less than Day One Biopharmaceuticals, Inc. (4.09), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Elevation Oncology, Inc. (41.10), less than Hepion Pharmaceuticals, Inc. (5.62),

Build a custom stock screener for Xeris Biopharma Holdings, Inc. (XERS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xeris Biopharma Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xeris Biopharma Holdings, Inc. (XERS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xeris Biopharma Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.